|
|
|
 |
|
 |
 |
|||
Company News
|
Takeda to Acquire Intellikine, Adding Two Novel Programs to its
Oncology Pipeline
Osaka, Japan, and La Jolla, California, 20 December 2011
top
Dicerna Pharmaceuticals Announces First DsiRNA Therapeutic Candidate Selected for Development, Triggering $5 Million Milestone Payment
KHK Exercises Option for Additional Oncology Target
Watertown, Mass., 15 December 2011
top
Portola Pharmaceuticals Announces Completion of $89 Million Financing
Company to Initiate Betrixaban Phase 3 Clinical Program in
Acute Medically Ill Indication in First Half of 2012
SOUTH SAN FRANCISCO, Calif, 21 November 2011
top
BIOGEN IDEC AND PORTOLA PHARMACEUTICALS ANNOUNCE GLOBAL COLLABORATION FOR ORAL SYK INHIBITOR PROGRAM TARGETING AUTOIMMUNE AND INFLAMMATORY DISEASES
-- Biogen Idec to Provide Portola with $45 Million
Upfront and up to $508.5 Million in Milestone Payments --
Weston, MA., and South San Francisco, CA, 27 October 2011
top
Valeritas Announces $150 Million Financing
•Welsh, Carson, Anderson & Stowe led the financing and assumes a controlling interest in Valeritas
•Financing will support the commercialization of the V-Go™ Disposable Insulin Delivery Device with a primary focus on adult patients with Type 2 diabetes who require insulin
Bridgewater, NJ, 12 September 2011
top
EISAI TO ACCELERATE LATE-STAGE CLINICAL DEVELOPMENT OF NEW DRUGS BY EFFECTIVELY LEVERAGING EXTERNAL RESOURCES
~Enters Collaborative Development Agreement with SFJ Pharmaceuticals for
Anticancer Agent E7080 (lenvatinib)~
Tokyo, Japan, 07 September 2011
top
Stanmore receives £4m investment from Imperial Innovations Group plc
Proceeds to finance expansion of distribution in UK and US and new product development
Elstree, UK, 20 July 2011
top
Magellan Biosciences Sells TREK Microbiology Business to Thermo Fisher Scientific
Chelmsford, MA, 18 July 2011
top
Micromet Announces Solid Tumor BiTE Antibody Collaboration with Amgen
- Collaboration on up to three targets and two programs
- Upfront payment of EUR 10 million upon deal execution
- Maximum deal value of EUR 695 million plus royalties and development cost reimbursement
Rockville, MD, 11 July 2011
top
Zogenix Enters $30 Million Royalty Financing Agreement With Cowen Healthcare Royalty Partners II
Includes an Additional $1.5 Million Equity Investment
San Diego, CA, 30 June 2011
top
Agreement Signed with Leading Healthcare Imaging Company
Stockholm, Sweden, 29 June 2011
top
Medicare Covers the Pathwork® Tissue of Origin Test
Helps Diagnose Metastatic and Other Difficult to Diagnose Cancers
Redwood City, CA, 13 June 2011
top
Positive Outcome of Interim Analysis of pivotal Alpharadin study: Primary endpoint met in Phase III ALSYMPCA study
Alpharadin is in development for treating bone metastases in patients with castration-resistant prostate cancer
Oslo, Norway, 06 June 2011
top
MD On-Line Announces Equity Investment from Abingworth
First Institutional Investor in Company’s History to Fuel Corporate Growth and Expansion
Parsippany, New Jersey, 18 May 2011
top
Lombard Medical Technologies PLC
Issue of equity to raise up to £27.5 million to fund U.S. approval and launch of Aorfix™
London, UK, 20 April 2011
top
Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C
Results position AMR101 to be first-in-class product for treatment of high triglycerides
Mystic, Connecticut and Dublin, Ireland, 18 April 2011
top
SUPERGEN AND ASTEX THERAPEUTICS ENTER DEFINITIVE MERGER AGREEMENT
Dublin, N, California and Cambridge, UK, 06 April 2011
top
Valeritas Receives FDA 510(k) Clearance for the V-Go™ Disposable Insulin Delivery Device for Use with NovoLog®
NovoLog® and Humalog® tested and found to be safe for use with the V-Go™ Disposable Insulin Delivery Device
Bridgewater, NJ, 01 March 2011
top
|
Archive:
|
|||||||||||||||||||||||||||||||||||||||||||||
2013
Andrew Kay, President and CEO of Algeta
Abingworth set a highly professional tone from the beginning. The due diligence was detailed and incisive and this attention to detail continued as Algeta became one of their portfolio companies. It is Abingworth's support capability that really distinguishes them. This includes market analytics, finance, commercial intelligence, and search expertise for executive managers and board members. They have extensive networks with big companies, biotechs and banks that provides invaluable introductions and contacts. What is quite remarkable is that despite being one of many portfolio companies, everyone across the Abingworth organisation seems to know who you are and they are responsive and enthusiastic about thinking of ways to help, identifying opportunities, issues and solutions.